ストックスクリーナーアプリを入手
9.84
2.77%
-0.28
アフターアワーズ：
9.40
-0.44
-4.47%
Septerna Inc (SEPN) 最新ニュース
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Septerna Lands Massive $2.2B Novo Nordisk Partnership to Revolutionize Oral Diabetes and Obesity Treatments - Stock Titan
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance
Is It Time to Buy the Dip in Novo Nordisk Stock? - Investing.com
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside | FinancialContent - FinancialContent
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - Pharmaceutical Technology
This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MSN
Septerna Stock Spikes on Novo Nordisk Obesity Drug Deal - Wall Street Pit
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B - BioSpace
Peninsula biotech Septerna lands deal for oral GLP-1 weight-loss drugs, stock zooms higher - The Business Journals
Novo Nordisk (NVO) Partners with Septerna to Develop Obesity and Diabetes Drugs - GuruFocus
Novo Nordisk Rises on Weight-Loss Deal. Septerna Stock Gains Even More. - Barron's
Septerna and Novo Nordisk to collaborate on oral obesity and other cardiometabolic diseases - The Pharma Letter
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
First patient treated with prime editing - statnews.com
Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill - Yahoo Finance
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal (SEPN) - Bloomberg
$2.2 billion deal: Septerna and Novo Nordisk collaborate on obesity, cardiometabolic diseases - PharmaLive
novo-nordisk-partners-with-septerna-on-obesity-drugs - baha.com
Novo makes fresh obesity play with $2.2bn Septerna deal - Pharmaphorum
Novo Nordisk partners with Septerna on obesity drugs - breakingthenews.net
Novo to work with Septerna in hunt for oral obesity drugs - Yahoo Finance
Septerna jumps 60% after Novo Nordisk partnership to develop oral obesity drugs - TradingView
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies - Proactive financial news
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - marketscreener.com
Septerna Enters Major Collaboration with Novo Nordisk - TipRanks
Novo Nordisk, Septerna to collaborate to develop obesity pills - TipRanks
Septerna, Novo Nordisk To Collaborate - marketscreener.com
Septerna stock jumps on pact with Novo Nordisk (SEPN:NASDAQ) - Seeking Alpha
Novo Nordisk signs billion-dollar deal with biotech company Septerna - marketscreener.com
Septerna stock soars on Novo Nordisk collaboration By Investing.com - Investing.com Canada
Septerna stock soars on Novo Nordisk collaboration - Investing.com
Novo Nordisk strikes deal with Septerna to develop obesity pills - statnews.com
Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B - Endpoints News
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases - Yahoo Finance
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):